Siren Biotechnology
PrivateLast Round
Grant
Jun 26, 2026
Est. Valuation
$64.2M
Total Funding Raised
$48.43M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Siren Biotechnology is a biotechnology company developing Universal AAV Immuno-Gene Therapy, which combines AAV gene therapy and cytokine immunotherapy, to treat solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Siren Biotechnology Comparables
Compare Siren Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trogenix | 79% | |
| Hyperliquid Strategies Inc. | 77% | |
| Akamis Bio | 76% |
Siren Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 26, 2026 | ||||
| Crowdfunding | Mar 15, 2026 | ||||
| Crowdfunding | Nov 3, 2025 | ||||
| Series A | Apr 22, 2024 | ||||
| Grant | Nov 1, 2023 | ||||
Seed | Sep 1, 2021 |
Siren Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NZVC | Series A |
| Carnrite Ventures | Series A |
| Innovation Endeavors | Seed, Series A |
| Founders Fund | Crowdfunding, Series A, Seed |
| ARTIS Ventures | Series A, Seed |
| Lux Capital | Crowdfunding, Series A, Seed |
| California Institute for Regenerative Medicine | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Open roles increased to 8, 5x the trailing average.
- Jun 26, 2026
$8M grant from California Institute for Regenerative Medicine
Recent news
Latest coverage and updates
- hiresOct 14, 2026
On Oct 14th '26 in California, Siren Biotechnology appoints Peter Bross, MD, former Chief of the Oncology Branch at the FDA's Center for Biologics Evaluation and Research, to its Clinical and Scientific Advisory Board as it advances SRN-101 into clinical development.
Siren Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Siren Biotechnology's valuation, stock price, and market status.
Is Siren Biotechnology a public or private company?
Siren Biotechnology is a private company.
What is the current stock price of Siren Biotechnology?
Siren Biotechnology is a private company, so its shares have no public market price. Caplight tracks Siren Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Siren Biotechnology worth (valuation)?
Siren Biotechnology's valuation is estimated at $64.2M based on funding round data.
Can I buy Siren Biotechnology stock?
Siren Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Siren Biotechnology's last funding round?
Siren Biotechnology's most recent funding round was Grant on June 26, 2026.
Who are the main investors in Siren Biotechnology?
Key investors in Siren Biotechnology include Innovation Endeavors, Founders Fund, Lux Capital, KMAK Capital.
Will Siren Biotechnology IPO soon?
No public IPO plans have been announced for Siren Biotechnology.
How can I track Siren Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Siren Biotechnology's shares on secondary markets.